Hale Z. TOKLU, Ranjit BANWAIT, Sad ALQUADAN, Sarah WILSON, Dhaval UPADHYAY, Devina SINGH, Rima PATEL, Christopher BRAY

Administration of systemic steroids during hospitalization does not improve the clinical outcome in patients with Covid-19

The systemic steroids are recommended for cases with refractory septic shock or severe acute respiratory distress syndrome. Although systemic glucocorticoids help to resolve inflammation and treat cytokine storm, the time course for steroid use and which patients benefit from using systemic corticosteroids is unclear. In this study, we aimed to evaluate the therapeutic effect of corticosteroids in COVID-19 patients. Electronic medical records of hospitalized patients (n=7,980) from 178 hospitals across United States for confirmed COVID-19 between January 1st 2020 and May 8th 2020 were reviewed. Of the 7,980 patients, 3,951 (49.5%) were female and 4,029 (50.5%) were male. The mean age was 57.4 ± 19 years. Fifteen percent (n=1,219) died in hospital or were discharged to hospice care. Seventy-two percent (n=5,774) required non-ICU level of care, while 28% (n=2,206) of patients required ICU, and of those 1,157 (14.5%) needed ventilator support. The mean length of stay in the hospital was 6 days (range 0 – 84 days). Fourteen percent (n=1111) of patients received at least one dose of systemic steroids during hospitalization. Sixty precent of those had ICU level of care with 435 (39%) requiring ventilator support. Overall, the use of corticosteroids was associated with increased mortality (OR=1.273; p=0.0160) and 3.53 days longer hospital stay (p

PDF

___

[1] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Shi, ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-273.
[2] Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019- nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; 395(10225): 689-697.
[3] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Feng Z. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13): 1199-1207.
[4] CDC. United States COVID-19 Cases and Deaths by State. https://covid.cdc.gov/covid-datatracker/#cases_casesper100klast7days, (accessed on 4 May 2021).
[5] Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, Negri EM. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020; 18(6): 1517-1519.
[6] Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, Nebuloni M. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. Lancet Infect Dis. 2020; 20(10): 1135- 1140.
[7] Banwait RSS, Joshua K, Fishman TJ, Uma GI. Convalescent plasma in COVID-19. HCA Healthcare Journal of Medicine. 2020; 1(3):139-146.
[8] Jean SS, Lee PI, Hsueh P R. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020; 53(3): 436-443.
[9] Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. Jama. 2020; 323(19): 1897-1898.
[10] Mehta N, Mazer-Amirshahi M, Alkindi N, Pourmand A. Pharmacotherapy in COVID-19; a narrative review for emergency providers. Am J Emerg Med. 2020; 38(7): 1488-1493.
[11] Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, Smith L. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne). 2020; 7: 170.
[12] Siordia JA Jr, Bernaba M, Yoshino K, Ulhaque A, Kumar S, Bernaba M, Bergin E. Systematic and statistical review of coronavirus disease 19 treatment trials. SN Compr Clin Med. 2020; 2: 1120–11311.
[13] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
[14] Kolilekas L, Loverdos K, Giannakaki S, Vlassi L, Levounets A, Zervas E, Gaga M. Can steroids reverse the severe COVID-19 induced "cytokine storm"? J Med Virol. 2020; 92(11): 2866-2869.
[15] Sibila O, Agustí C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008; 32(2): 259-264.
[16] Stern A, Skalsky K, Avni T, Carrara E, Leibovici L, Paul M. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017; 12(12): CD007720.
[17] Yang JW, Yang L, Luo RG, Xu JF. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clin Microbiol Infect. 2020; 26(9): 1171-1177.
[18] Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019; 2(2): CD010406
[19] Nasim S, Kumar S, Azim D, Ashraf Z, Azeem Q. Corticosteroid use for 2019-nCoV infection: A double-edged sword. Infect Control Hosp Epidemiol. 2020; 41(10): 1244-1245.
[20] Tang C, Wang Y, Lv H, Guan Z, Gu J. Caution against corticosteroid-based COVID-19 treatment. Lancet. 2020; 395(10239): 1759-1760.
[21] WHO. Clinical management of COVID-19. https://www.who.int/publications-detail/clinical-management-ofsevere-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected, (accessed on 6 July 2020).
[22] Berton AM, Prencipe N, Giordano R, Ghigo E, Grottoli S. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view. J Endocrinol Invest. 2021; 44(4): 873-875.
[23] Chen RC, Tang XP, Tan SY, Liang BL, Wan ZY, Fang JQ, Zhong N. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129(6): 1441-1452.
[24] Wang y, Jiang W, He Q, Wang C, Liu B, Zhou P, Dong N, Tong Q. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv 2020.03.06.20032342:
[25] Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Villanueva EV. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020; 212(9): 416-420.
[26] Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, Pan A. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect. 2020; 81(1): 147-178.
[27] Ling Y, Xu SB, Lin YX, Tian D, Zhu ZQ, Dai FH, Lu HZ. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020; 133(9): 1039-1043.
[28] Wu, C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180(7): 934-943.
[29] Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020; 133(9): 1025-1031.
[30] Cruz AF, Ruiz-Antorán B, Múñez Rubio E, López AS, Callejas Díaz A, Avendaño-Solá C, Martínez AR. The right time for steroids in COVID-19. Clin Infect Dis. 2020; ciaa865.
[31] Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Landray MJ. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020; 384(8): 693-704.
[32] Selvaraj V, Dapaah-Afriyie K, Finn A, Flanigan TP. Short-term dexamethasone in Sars-CoV-2 patients. R I Med J. 2020; 103(6): 39-43.
[33] Fadel R, Morrison, AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, Ramesh MS. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020; 71(16): 2114-2120.
[34] National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial version 7). Chin Med J (Engl). 2020; 133(9): 1087-1095.
[35] Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, Sancho-López A, Mills-Sánchez P, Centeno-Soto G A, Avendaño-Solá C. A retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother. 2020; 64(9): e01168-20.
[36] Scaroni C, Armigliato M, Cannavò S. COVID-19 outbreak and steroids administration: are patients treated for SarsCov-2 at risk of adrenal insufficiency? J Endocrinol Invest. 2020; 43(7): 1035-1036.
[37] Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020; 55: 2001009
[38] Gangopadhyay KK, Mukherjee JJ, Sinha B, Ghosa S. The role of corticosteroids in the management of critically ill patients with coronavirus disease 2019 (COVID-19): A meta-analysis. medRxiv 2020.04.17.20069773.
[39] Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020; 81(1): e13-e20.